Full text is available at the source.
Gene Editing for Cystic Fibrosis: Advances and Prospects of CRISPR‐Cas9 Therapy
Gene Editing Using CRISPR-Cas9 for Treating Cystic Fibrosis: Progress and Future Possibilities
AI simplified
Abstract
Genome editing technologies may offer a permanent treatment for cystic fibrosis by correcting genetic mutations.
- Cystic fibrosis is caused by mutations in the CFTR gene, which is essential for maintaining water and salt balance in the body.
- Impairment of CFTR affects multiple organs, particularly the lungs.
- Current treatments, such as CFTR modulators, target specific mutations but have limited therapeutic potential.
- Genome editing technologies like CRISPR-Cas9 could potentially correct various CFTR mutations.
- The review discusses the development and prognosis of cystic fibrosis, alongside advancements in gene editing for treatment.
AI simplified